The PitA protein contributes to colistin susceptibility in Pseudomonas aeruginosa.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 03 08 2023
accepted: 28 09 2023
medline: 2 11 2023
pubmed: 12 10 2023
entrez: 12 10 2023
Statut: epublish

Résumé

Pseudomonas aeruginosa is an opportunistic pathogen that causes a wide range of problematic infections in individuals with predisposing conditions. Infections can be treated with colistin but some isolates are resistant to this antibiotic. To better understand the genetic basis of resistance, we experimentally evolved 19 independent resistant mutants from the susceptible laboratory strain PAO1. Whole genome sequencing identified mutations in multiple genes including phoQ and pmrB that have previously been associated with resistance, pitA that encodes a phosphate transporter, and carB and eno that encode enzymes of metabolism. Individual mutations were engineered into the genome of strain PAO1. Mutations in pitA, pmrB and phoQ increased the minimum inhibitory concentration (MIC) for colistin 8-fold, making the bacteria resistant. Engineered pitA/phoQ and pitA/pmrB double mutants had higher MICs than single mutants, demonstrating additive effects on colistin susceptibility. Single carB and eno mutations did not increase the MIC suggesting that their effect is dependent on the presence of other mutations. Many of the resistant mutants had increased susceptibility to β-lactams and lower growth rates than the parental strain demonstrating that colistin resistance can impose a fitness cost. Two hundred and fourteen P. aeruginosa isolates from a range of sources were tested and 18 (7.8%) were colistin resistant. Sequence variants in genes identified by experimental evolution were present in the 18 resistant isolates and may contribute to resistance. Overall our results identify pitA mutations as novel contributors to colistin resistance and demonstrate that resistance can reduce fitness of the bacteria.

Identifiants

pubmed: 37824582
doi: 10.1371/journal.pone.0292818
pii: PONE-D-23-24646
pmc: PMC10569645
doi:

Substances chimiques

Colistin Z67X93HJG1
Bacterial Proteins 0
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0292818

Informations de copyright

Copyright: © 2023 Erdmann et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Nat Protoc. 2008;3(2):163-75
pubmed: 18274517
Antimicrob Agents Chemother. 2009 Jun;53(6):2298-305
pubmed: 19332669
BMC Bioinformatics. 2016 Apr 19;17:172
pubmed: 27094401
Drugs Context. 2018 May 29;7:212527
pubmed: 29872449
Clin Microbiol Rev. 2020 May 13;33(3):
pubmed: 32404435
Nat Protoc. 2015 Nov;10(11):1820-41
pubmed: 26492139
Infect Drug Resist. 2022 Dec 14;15:7271-7292
pubmed: 36540105
FEMS Microbiol Lett. 2018 Jul 1;365(14):
pubmed: 29897457
Drugs. 2021 Dec;81(18):2117-2131
pubmed: 34743315
Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0269620
pubmed: 33875431
Front Med (Lausanne). 2021 Aug 12;8:677720
pubmed: 34476235
Antimicrob Agents Chemother. 2019 Sep 23;63(10):
pubmed: 31383668
Antibiotics (Basel). 2022 Jul 01;11(7):
pubmed: 35884138
FEMS Microbiol Lett. 2009 May;294(2):127-32
pubmed: 19431232
Infect Dis Clin North Am. 2020 Dec;34(4):723-750
pubmed: 33011049
Nat Rev Microbiol. 2010 Apr;8(4):260-71
pubmed: 20208551
Diagn Microbiol Infect Dis. 2014 Mar;78(3):271-6
pubmed: 24412662
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Int J Antimicrob Agents. 2017 Jun;49(6):767-769
pubmed: 28392440
Int Microbiol. 2022 Nov;25(4):709-721
pubmed: 35697891
Emerg Microbes Infect. 2020 Dec;9(1):868-885
pubmed: 32284036
Int J Antimicrob Agents. 2017 May;49(5):526-535
pubmed: 28163137
Eur J Biochem. 1983 Jan 1;129(3):697-702
pubmed: 6402363
Adv Microbiol. 2012 Mar 1;2(1):
pubmed: 24349887
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28630206
J Antimicrob Chemother. 2019 Jul 1;74(7):1825-1835
pubmed: 30989186
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0099222
pubmed: 36346250
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115557
pubmed: 34673293
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31010862
Mol Microbiol. 2003 Oct;50(1):205-17
pubmed: 14507375
Expert Rev Anti Infect Ther. 2013 Mar;11(3):297-308
pubmed: 23458769
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29263076
Mol Biol Rep. 2021 Mar;48(3):2897-2907
pubmed: 33839987
Antimicrob Agents Chemother. 2012 Feb;56(2):1019-30
pubmed: 22106224
PLoS One. 2012;7(10):e46688
pubmed: 23056405
Mol Microbiol. 2015 Jul;97(1):166-78
pubmed: 25846400
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
Science. 2016 Jan 1;351(6268):aad3292
pubmed: 26722002
Front Microbiol. 2014 Nov 26;5:643
pubmed: 25505462
Clin Microbiol Infect. 2021 Nov;27(11):1631-1637
pubmed: 34015532
Nat Commun. 2016 Oct 03;7:13002
pubmed: 27694971
Microb Genom. 2021 Nov;7(11):
pubmed: 34826267
Cell. 2018 Jan 11;172(1-2):121-134.e14
pubmed: 29307490
Nucleic Acids Res. 1997 Sep 1;25(17):3389-402
pubmed: 9254694
Nucleic Acids Res. 2016 Jan 4;44(D1):D646-53
pubmed: 26578582
Front Microbiol. 2021 Oct 27;12:778968
pubmed: 34777328
Elife. 2021 Apr 06;10:
pubmed: 33821795
Gene. 1998 May 28;212(1):77-86
pubmed: 9661666
Genome Biol Evol. 2019 Jan 1;11(1):109-120
pubmed: 30496396
J Bacteriol. 2012 Dec;194(23):6387-9
pubmed: 22984262
Genome Biol. 2019 Nov 28;20(1):257
pubmed: 31779668
Genes Dis. 2019 Apr 17;6(2):109-119
pubmed: 31194018
Antimicrob Agents Chemother. 2019 Sep 30;63(12):
pubmed: 31570397
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
Front Microbiol. 2020 May 25;11:1013
pubmed: 32528441
Front Microbiol. 2018 Feb 12;9:153
pubmed: 29483899
Methods Mol Biol. 2014;1151:165-88
pubmed: 24838886
Front Microbiol. 2015 Sep 29;6:1036
pubmed: 26483767
Innate Immun. 2009 Oct;15(5):261-312
pubmed: 19710102
J Bacteriol. 2012 Feb;194(4):813-26
pubmed: 22155771

Auteurs

Mareike B Erdmann (MB)

Department of Biochemistry, University of Otago, Dunedin, New Zealand.

Paul P Gardner (PP)

Department of Biochemistry, University of Otago, Dunedin, New Zealand.

Iain L Lamont (IL)

Department of Biochemistry, University of Otago, Dunedin, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH